Advances in Peptide Receptor Radionuclide Therapy

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Peptide receptor radionuclide therapy (PRRT) is a key treatment for advanced neuroendocrine tumors (NETs).
• Growing evidence supports PRRT's role, but higher-level evidence from prospective trials is anticipated.
• Methodological advancements are ongoing in radiopharmaceuticals, drug combinations, and administration routes.

Purpose of the Study:

• To review the current status and future directions of PRRT for advanced NETs.
• To highlight potential improvements in PRRT efficacy and patient outcomes.
• To discuss emerging strategies and their impact on clinical practice.

Main Methods:

• Review of cumulative evidence from retrospective and prospective studies on PRRT.
• Analysis of ongoing methodological improvements in radionuclide therapy.
• Discussion of novel approaches like intraarterial administration and drug combinations.

Main Results:

• PRRT is a highly effective targeted therapy for advanced NETs.
• Intraarterial PRRT may benefit liver-dominant metastatic disease, requiring further definition of patient selection and benefit.
• Combining PRRT with cytotoxic or radiosensitizing drugs shows promise for pancreatic NETs.

Conclusions:

• PRRT is a cornerstone in advanced NET treatment, with significant potential for improvement.
• Future research will likely focus on optimizing PRRT through novel radiopharmaceuticals, drug combinations, and administration strategies.
• Somatostatin-receptor antagonists and other advancements may enhance PRRT's benefit-toxicity ratio, potentially establishing new standards of care.